33.18 0.00 (0.00%)
After hours: 5:17PM EDT
|Bid||32.25 x 900|
|Ask||37.20 x 1300|
|Day's Range||32.12 - 33.55|
|52 Week Range||8.67 - 34.50|
|Beta (3Y Monthly)||1.22|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Ra Pharmaceuticals, Inc. (RARX) today announced the U.S. Food and Drug Administration’s (FDA) clearance of the Company’s Investigational New Drug (IND) application for zilucoplan for the treatment of immune-mediated necrotizing myopathy (IMNM). The Company is on track to initiate a Phase 2 clinical trial in the second half of 2019. “Patients with IMNM face a severe, chronic, debilitating autoimmune disease with limited treatment options and no approved therapies,” said Andrew Mammen, M.D., Ph.D., Muscle Disease Unit Leader, Laboratory of Muscle Stem Cells and Gene Regulation, and Principal Investigator for the Phase 2 study at the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD.
Ra Pharmaceuticals, Inc. today announced that senior management will present at the following upcoming investor conferences:
Phase 2 gMG long-term extension data show durability of zilucoplan treatment effect, with sustained improvements in primary and secondary endpoints observed at 24 weeks
Open-label, long-term extension data show durability of zilucoplan treatment effect, with sustained improvements observed in primary and secondary endpoints at 24 weeks
Ra Pharmaceuticals, Inc. (RARX) today presented pre-clinical data for an extended release (XR) formulation of zilucoplan at the 6th Annual Peptides Congress, taking place April 24-25, 2019, in London, UK. The PLGA XR formulation of zilucoplan is designed to produce uniform particles with homogenous distribution of zilucoplan and a predictable release profile.
Ra Pharmaceuticals, Inc. (RARX) today announced the successful completion of End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA) for its Phase 3 clinical trial of zilucoplan for the treatment of generalized myasthenia gravis (gMG). Based on feedback provided by the FDA, Ra Pharma plans to initiate a single, pivotal, Phase 3, randomized, double-blind, placebo-controlled trial evaluating the efficacy of a once-daily, subcutaneously (SC) self-administered dose of 0.3 mg/kg of zilucoplan versus placebo. The trial is expected to enroll approximately 130 patients with gMG who are acetylcholine receptor (AChR)-antibody-positive, regardless of their prior therapies.
Ra Pharmaceuticals, Inc. (RARX) today announced that data from its Phase 2 clinical trial of zilucoplan for the treatment of generalized myasthenia gravis (gMG) have been selected for an Emerging Science dual oral and poster presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia, PA, from May 4 to 10, 2019. The presentation will feature data from the Phase 2, randomized, double-blind, placebo-controlled clinical trial, as well as data from the open-label, long-term extension study. Ra Pharma is developing zilucoplan for generalized myasthenia gravis (gMG), paroxysmal nocturnal hemoglobinuria (PNH), and other complement-mediated disorders.
Successful completion of Phase 2 trial of zilucoplan in generalized myasthenia gravis with rapid, clinically meaningful, and statistically significant reductions in QMG and M
Ra Pharmaceuticals, Inc. today announced that Doug Treco, Ph.D., President and Chief Executive Officer of Ra Pharma, will present at the Cowen 39th Annual Health Care Conference on Monday, March 11, 2019 at 1:30 p.m.
Ra Pharmaceuticals, Inc. (RARX) today joins forces with 30 million healthcare advocates around the world for the 12th Annual Rare Disease Day®, an awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges people living with rare diseases face. “Despite important scientific advances in the treatment of rare diseases, there remains significant work to be done to help patients and families. At Ra Pharma, we are focused on developing medicines to treat patient populations with complement-mediated diseases and are committed to expanding patient access to more convenient life-saving medicines,” said Doug Treco, Ph.D., President and Chief Executive Officer of Ra Pharma.
Ra Pharmaceuticals, Inc. today announced that Ramin Farzaneh-Far, M.D., Chief Medical Officer of Ra Pharma, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 2:30 p.m.
Ra Pharmaceuticals, Inc. (RARX) (“Ra Pharma”) today announced the pricing of an underwritten public offering of 8,387,097 shares of its common stock, at a public offering price of $15.50 per share, before underwriting discounts and commissions. Ra Pharma also granted the underwriters a 30-day option to purchase up to an additional 1,258,064 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $130.0 million, excluding any exercise of the underwriters' option to purchase additional shares.
Ra Pharmaceuticals, Inc. (RARX) (“Ra Pharma”) today announced that it intends to offer and sell, subject to market and other conditions, $100 million of its common stock in an underwritten public offering. Ra Pharma expects to grant the underwriters a 30-day option to purchase up to $15 million of additional shares of its common stock. Jefferies, BMO Capital Markets, and Stifel are acting as joint book-running managers for the offering.
Ra Pharmaceuticals, Inc. (RARX) today announced positive top-line results from the Company’s Phase 2 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gMG), achieving clinically meaningful and statistically significant reductions in both the primary and key secondary endpoints for both zilucoplan dose groups tested versus placebo at 12 weeks.
Ra Pharmaceuticals, Inc. (RARX) today announced that it has received a development milestone payment under its collaboration agreement with Merck, known as MSD outside the US and Canada. The milestone payment is associated with the companies’ collaboration for a non-complement cardiovascular target with a large market opportunity. Initiated in 2013, this collaboration leverages Ra Pharma’s Extreme Diversity™ platform aimed at producing macrocyclic peptides that have the diversity and specificity of antibodies, while retaining the pharmacologic attributes of small molecules.
Ra Pharmaceuticals, Inc. (RARX) today announced the election of Bo Cumbo to its board of directors. Mr. Cumbo is a veteran of the biotechnology industry and has played strategically important roles in the successful launch of 11 products across multiple organizations and therapeutic categories, including rare neuromuscular diseases, hepatitis, HIV, and cardiovascular disease. “In his more than twenty-year career in the biotechnology and pharmaceutical sectors, Bo has played an integral role in the planning and implementation of numerous, highly successful and industry-leading commercial product launches,” said Doug Treco, PhD, President and Chief Executive Officer of Ra Pharma.
Dosing completed in Phase 2 trial of zilucoplan in generalized myasthenia gravis
Ra Pharmaceuticals, Inc. (RARX) today announced positive results from the Company’s Phase 1b pharmacokinetic (PK) study evaluating zilucoplan (RA101495 SC) in patients with renal impairment. The Company has received International Nonproprietary Names (INN) clearance for use of the name zilucoplan from the World Health Organization. The Phase 1b, multi-center, open-label trial was designed to evaluate the PK profile of zilucoplan in patients with severe renal impairment as a lead-in to studying zilucoplan in complement-mediated renal disorders.
Ra Pharmaceuticals, Inc. today announced that Doug Treco, PhD, President and Chief Executive Officer of Ra Pharma, will present at the 2018 Cantor Global Healthcare Conference on Tuesday, October 2, 2018 at 9:10 a.m.
Ra Pharmaceuticals, Inc. (RARX) today announced the election of Aoife M. Brennan, M.B., B.Ch., to its board of directors. “Dr. Brennan has an impressive track record of success in advancing the development of numerous drug candidates throughout her career, with experience in the fields of rare disease, hematology, and neurology, among other key therapeutic areas,” said Doug Treco, PhD, President and Chief Executive Officer of Ra Pharma. Dr. Brennan joined Synlogic in 2016 from Biogen, where she most recently served as Vice President and Head of the Rare Disease Innovation Unit, which included programs ranging from pre-clinical to commercial.
Ra Pharmaceuticals, Inc. (RARX) today announced the completion of End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA) for its global Phase 3 program of RA101495 SC for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Based on feedback provided by FDA during End-of-Phase 2 discussions regarding the Company’s planned global Phase 3 PNH program, as well as advice previously provided by the Medicines and Healthcare products Regulatory Agency in the United Kingdom (MHRA) and Health Canada, Ra Pharma plans to initiate a global, pivotal, single-arm Phase 3 trial to evaluate the safety and efficacy of RA101495 SC in approximately 40 treatment-naïve PNH patients.
Surpassed target enrollment in Phase 2 trial of RA101495 SC for gMG